Drug Type Immune cell therapy |
Synonyms- |
Target- |
Action- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fanconi Anemia | Phase 2 | United States | 29 Jan 2002 | |
Leukemia | Phase 2 | United States | 29 Jan 2002 | |
Multiple Myeloma | Phase 2 | United States | 29 Jan 2002 | |
Myelodysplastic Syndromes | Phase 2 | United States | 29 Jan 2002 | |
Myelodysplastic-Myeloproliferative Diseases | Phase 2 | United States | 29 Jan 2002 | |
Myeloproliferative Disorders | Phase 2 | United States | 29 Jan 2002 |
Phase 2 | 41 | peripheral blood stem cell transplantation+methylprednisolone+fludarabine phosphate+cyclophosphamide+therapeutic allogeneic lymphocytes+Tacrolimus+sargramostim+mycophenolate mofetil | paadzbqcwb = htsikrebaa xsbjvlrnkm (ftsqtbctyt, gvxxffheuv - djazbotjwb) View more | - | 10 Feb 2020 |